Figure 1 | Scientific Reports

Figure 1

From: The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease

Figure 1The alternative text for this image may have been generated using AI.

Preventive effect of saroglitazar on diet-induced obesity in DIAMOND mice. DIAMOND mice (B6/129 mice) were fed chow diet (CDNW) or high fructose/glucose, high fat western diet (WDSW) for up to 12 weeks to develop fatty liver and steatohepatitis. Mice were administered pioglitazone, saroglitazar or vehicle control along with CDNW or WDSW for an additional 12 weeks. (A) Body weight, (B) liver weight, (C) fasting glucose, (D) fasting insulin, (E) HOMA-IR, (F) serum triglycerides. Data are expressed as the mean ± SEM for 6–12 mice per group. ##p < 0.001 compared to CDNW; *p < 0.05, **p < 0.001 compared to WDSW, vehicle control.

Back to article page